Non-Invasive Ventilation in Immunocompromised Patients with Respiratory Failure

Area of Science:

• Critical Care Medicine
• Pulmonology
• Oncology

Background:

• Non-invasive ventilation (NIV) was favored for immunocompromised patients with acute respiratory failure (ARF) to avoid invasive ventilation.
• Historically, tracheal intubation had high mortality in this population.
• Recent advances in cancer therapy, ICU care, and triage have improved outcomes for intubated patients.

Purpose of the Study:

• To re-evaluate the role of NIV in immunocompromised patients with ARF.
• To identify predictors of NIV failure in this population.
• To guide ventilation strategies and determine optimal timing for intubation.

Main Methods:

• Review of evolving evidence on NIV and intubation outcomes in immunocompromised patients with ARF.
• Analysis of factors influencing survival, including intubation criteria, immunosuppression causes, and patient severity.
• Discussion of the emergence of high-flow nasal cannula (HFNC) oxygenation.

Main Results:

• Mortality for intubated immunocompromised patients has decreased.
• Survival is influenced by inconsistent intubation criteria, immunosuppression type, and severity.
• Poor ICU outcomes are noted in specific oncohematologic and frail patient subgroups.
• No validated tools exist to predict NIV success or failure.

Conclusions:

• Immunocompromised patients with ARF may benefit from strategies similar to the general population, including timely intubation.
• Careful bedside assessment is crucial to guide NIV use and prevent delays in intubation.
• HFNC oxygenation is a new tool being investigated for ARF in critically ill patients, including the immunocompromised.